Colorcon, Inc., a global leader in pharmaceutical film coatings and specialty excipients, today announces that it has entered into a Put agreement to purchase Airnov Healthcare Packaging, portfolio company of Arsenal Capital Partners, a private equity firm. The transaction, which is subject to French Works Council review and subject to necessary regulatory approvals, could close during the first quarter of 2023.
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen; this includes customizable, high-quality drop-in products (canisters and packets), integrated desiccant systems and specially designed plastic bottles containing oxygen barrier materials. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people. This aligns well with Colorcon’s portfolio and its purpose to improve health and wellness through convenience, compliance and safety.
Simon Tasker, CEO, Colorcon explains “The acquisition presents a good match for our companies as a key strength of Colorcon is the breadth of customer relationships across the pharmaceutical industry, including contacts at all levels in R&D, supply chain, and procurement. The addition of Airnov would be complementary to Colorcon’s portfolio and provide synergies in terms of technical, customer and regulatory support to accelerate our customers’ product development and commercialization.”
Matthias Brommer, President and Managing Director, Airnov says “Colorcon’s ownership would bring improved geographic coverage and provide our customers added value through their pharma focus and complementary product portfolio. Colorcon understands the impact of speed to market in the competitive, fast-paced pharmaceutical industry and would help us to support our customers in the production of highly effective products in reduced time frames.”
For over 60 years Colorcon has consistently delivered superior products and support services to the pharmaceutical, nutritional, and animal health industries across the world.
Simon Tasker adds “This contemplated acquisition reflects Colorcon’s goal to invest in innovative solutions that help our customers increase speed to market while leveraging our scale and infrastructure to deliver dependability and consistency for the supply of health and wellness products around the world.”
Source: prnewswire.com
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
